Resolve BioSciences GmbH

Based in Germany, Resolve BioSciences GmbH specializes in innovative spatial analysis technology, particularly through its Molecular Cartography platform, addressing complex biological challenges in critical fields like oncology and infectious diseases. Resolve BioSciences GmbH, founded in 2012 in Germany, focuses on advanced spatial analysis solutions for the life sciences sector. The company has executed 2 deals, with the most recent being a Series B funding round on August 4, 2022, which raised USD 71. 00 mn, led by Patient Square Capital with participation from various investors.

The founders, Axel Heinemann and Peer Schatz, pioneered efforts in spatial analysis technologies. Currently led by CEO John Stark, the company has not undergone any significant pivots or changes in its business operations. Resolve Biosciences specializes in innovative spatial analysis technology through its flagship product, the Molecular Cartography platform. This platform is designed to tackle complex biological challenges in fields such as oncology, neuroscience, and infectious disease.

It enables scientists to achieve highly multiplexed spatial analysis, producing comprehensive data sets that elucidate molecular interactions at subcellular resolution while preserving tissue integrity. Initial applications focus on providing high-resolution insights into transcriptomic activity, allowing for the interrogation of hundreds of genes in one run. The technology has been accessible since its development began in 2016 and is marketed primarily to research institutions, biotechnology companies, and pharmaceutical firms in North America, Europe, and parts of Asia. Resolve Biosciences generates revenue through the provision of its Molecular Cartography platform and related services, typically offered under a subscription model or direct service agreements with clients in the life sciences sector.

Clients, including academic research institutions and commercial laboratories, utilize the platform for advanced research in various biomedical fields. Revenue streams are bolstered by service contracts that facilitate access to the technology for specific projects or ongoing research needs, aligning with clients' budgets and research objectives. In August 2022, Resolve BioSciences GmbH raised USD 71. 00 mn in Series B funding, which will be used for product development and to accelerate operations.

The company plans to expand its product offerings and may target new geographic markets, although specific new regions have not been disclosed. Recent funding will support these initiatives, aiming to enhance product capabilities and market reach.